COVID-19 Results Briefing

European Union

April 08, 2021

This document contains summary information on the latest projections from the IHME model on COVID-19 in the European Union. The model was run on April 6, 2021, with data through April 5, 2021.

Declines in reported daily cases are likely an artifact of delayed reporting over the Easter holidays. We expect that transmission is still increasing in the majority of countries in the EU. While transmission is still increasing and deaths are now climbing slowly, we expect that the combination of rising vaccination, declining seasonality, and sustained levels of mask use should be enough to lead to a peak in daily deaths by late April or early May. Faster reductions in mask use or increases in mobility captured in our worse scenario show that daily deaths can easily remain higher through to August 1. There is very limited spread of the escape variants (B.1.351 and P1), and the dominant variant in the entirety of the EU is B.1.1.7. This suggests that escape variants may only become a major issue in the region later in the year. The most important strategies to pursue at this point in the pandemic are accelerated vaccination, maintenance of high levels of mask use as well as expansion of mask use in several countries, and appropriate implementation of social distancing mandates where transmission continues to climb. Much lower vaccine confidence in the Baltic countries, Romania, Bulgaria, Cyprus, and Luxembourg is a concern given the critical role of vaccination scale-up in controlling this phase of the epidemic.

Current situation

- Daily reported cases in the last week decreased to 126,100 per day on average compared to 161,700 the week before (Figure 1). This is likely an artifact of delayed reporting over the Easter holidays.
- Daily deaths in the last week increased to 2,500 per day on average, compared to 2,400 the week before (Figure 2). This makes COVID-19 the number 2 cause of death in the European Union this week (Table 1).
- The daily death rate is greater than 4 per million in 12 r Member States (Figure 3).
- We estimated that 15% of people in the European Union have been infected or re-infected as of April 5 (Figure 4).
- Effective R, computed using cases, hospitalizations, and deaths, is greater than 1 in most Member States, including all regions of Germany and several regions of Italy and Spain (Figure 5).
- The infection detection rate in the European Union was close to 54% on April 5 (Figure 6).

- Based on the publicly reported sequencing data and our variant spread model, we estimate the current prevalence of key variants in the EU (Figure 7). B.1.1.7 is the dominant variant in nearly all countries of the EU. Escape variants (B.1.351 and P1) are present in several countries but have not yet spread widely, according to the available data.
- Variant B.1.351 has been reported in Austria, Belgium, Greece, Lithuania, and the Netherlands, while variant P1 has been reported in Czechia and Luxembourg (Figure 7).

Trends in drivers of transmission

- Some mandates have been lifted in Czechia. Further mandates have been imposed in Denmark, France, and Slovenia. **The overall level of mandates is at its highest level since May 2020.**
- Mobility last week was 37% lower than the pre-COVID-19 baseline (Figure 9). Mobility was near baseline (within 10%) in Croatia.
- As of April 5, we estimated that 71% of people in the European Union always wore a mask when leaving their home (Figure 11). Mask use was lower than 50% in Sweden, Denmark, the Netherlands, and Croatia.
- There were 439 diagnostic tests per 100,000 people on April 5 (Figure 13).
- In the European Union, 80.3% of people say they would accept or would probably accept a vaccine for COVID-19. The fraction of the population open to receiving a COVID-19 vaccine ranges from 34% in Latvia to 91 in Denmark (Figure 17).
- In our current reference scenario, we expect that 438 million people in the EU will be vaccinated by August 1 (Figure 18). Vaccination is likely to become demand-constrained by late June.

Projections

- Under our **reference scenario**, which represents what we think is most likely to happen, our model projects 774,000 cumulative deaths on August 1, 2021. This represents 138,000 additional deaths from April 5 to August 1 (Figure 19). Daily deaths will peak by early May, and then start declining (Figure 20).
- If **universal mask coverage (95%)** were attained in the next week, our model projects 16,000 fewer cumulative deaths compared to the reference scenario on August 1 (Figure 19).
- Under our **worse scenario**, our model projects 809,000 cumulative deaths on August 1, 2021, an additional 35,000 deaths compared to our reference scenario (Figure 19). Daily deaths would remain over 500 on August 1 in this scenario.
- By August 1, we project that 69,300 lives will be saved by the projected vaccine rollout. This does not include lives saved through vaccination that has already been delivered.

- In the worse scenario, daily infections remain over 100,000 by early June and over 50,000 on August 1 (Figure 21).
- Figure 22 compares our reference scenario forecasts to other publicly archived models. IHME and Imperial models suggest a peak in daily deaths by early May. Other models suggests declining daily deaths from now forward.
- At some point from April through August 1, eight Member States will have high or extreme stress on hospital beds (Figure 23). At some point from April through August 1, five Member States will have high or extreme stress on ICU capacity (Figure 24).

Model updates

There are no major updates in the model this week.

Figure 1. Reported daily COVID-19 cases



Table 1. Ranking of COVID-19 among the leading causes of mortality this week, assuming uniform deaths of non-COVID causes throughout the year

Cause name	Weekly deaths	Ranking
Ischemic heart disease	18,714	1
COVID-19	17,735	2
Stroke	10,303	3
Tracheal, bronchus, and lung cancer	6,216	4
Alzheimer's disease and other dementias	5,827	5
Chronic obstructive pulmonary disease	4,608	6
Colon and rectum cancer	4,100	7
Lower respiratory infections	3,503	8
Hypertensive heart disease	2,797	9
Chronic kidney disease	2,430	10

Figure 2. Reported daily COVID-19 deaths



Figure 3. Daily COVID-19 death rate per 1 million on April 05, 2021



Figure 4. Estimated percent of the population infected with COVID-19 on April 05, 2021



Figure 5. Mean effective R on March 25, 2021. The estimate of effective R is based on the combined analysis of deaths, case reporting, and hospitalizations where available. Current reported cases reflect infections 11-13 days prior, so estimates of effective R can only be made for the recent past. Effective R less than 1 means that transmission should decline, all other things being held the same.



Figure 6. Percent of COVID-19 infections detected. This is estimated as the ratio of reported daily COVID-19 cases to estimated daily COVID-19 infections based on the SEIR disease transmission model.



*Due to measurement errors in cases and testing rates, the infection to detection rate (IDR) can exceed 100% at particular points in time.

Figure 7. Percent of circulating SARS-CoV-2 for 3 primary variants on April 5, 2021.

A. Percent B.1.1.7 variant



B. Percent B.1.351 variant



C. Percent P1 variant



Figure 8. Infection fatality ratio on April 05, 2021. This is estimated as the ratio of COVID-19 deaths to infections based on the SEIR disease transmission model.



Critical drivers

Table 2. Current mandate implementation



*Not all locations are measured at the subnational level.

Figure 9. Trend in mobility as measured through smartphone app use compared to January 2020 baseline



Figure 10. Mobility level as measured through smartphone app use compared to January 2020 baseline (percent) on April 05, 2021



Figure 11. Trend in the proportion of the population reporting always wearing a mask when leaving home



Figure 12. Proportion of the population reporting always wearing a mask when leaving home on April 05, 2021



Figure 13. Trend in COVID-19 diagnostic tests per 100,000 people



Figure 14. COVID-19 diagnostic tests per 100,000 people on April 01, 2021



Figure 15. Increase in the risk of death due to pneumonia on February 1 2020 compared to August 1 2020



Table 3. The SEIR model uses variant-specific estimates of vaccine efficacy at preventing symptomatic disease and at preventing infection. We use data from clinical trials directly, where available, and make estimates otherwise. More information can be found on our website (http://www.healthdata.org/node/8584).

Vaccine	Efficacy at preventing disease: D614G & B.1.1.7	Efficacy at preventing infection: D614G & B.1.1.7	Efficacy at preventing disease: B.1.351 & P.1	Efficacy at preventing infection: B.1.351 & P.1
AstraZeneca	75%	52%	10%	7%
CanSinoBio	66%	57%	50%	44%
CoronaVac	50%	43%	38%	33%
Johnson & Johnson	72%	72%	64%	56%
Moderna	94%	85%	72%	62%
Novavax	89%	77%	49%	43%
Pfizer/BioNTech	91%	86%	69%	61%
Sinopharm	73%	63%	56%	48%
Sputnik V	92%	80%	70%	61%
Other mRNA vaccines	95%	83%	72%	63%
All other vaccines	75%	65%	57%	50%

Figure 16. Trend in the estimated proportion of the adult (18+) population that has been vaccinated or is open to receiving a COVID-19 vaccine based on Facebook survey responses (yes and yes, probably).



Figure 17. This figure shows the estimated proportion of the adult (18+) population that have been vaccinated or is open to receiving a COVID-19 vaccine based on Facebook survey responses (yes and yes, probably).



Figure 18. The number of people who receive any vaccine and those who are effectively vaccinated and protected against disease, accounting for efficacy, loss to follow up for two-dose vaccines, partial immunity after one dose, and immunity after two doses.



Projections and scenarios

We produce three scenarios when projecting COVID-19. The **reference scenario** is our forecast of what we think is most likely to happen:

- Vaccines are distributed at the expected pace.
- Governments adapt their response by re-imposing social distancing mandates for 6 weeks whenever daily deaths reach 8 per million, unless a location has already spent at least 7 of the last 14 days with daily deaths above this rate and not yet re-imposed social distancing mandates. In this case, the scenario assumes that mandates are re-imposed when daily deaths reach 15 per million.
- Variants B.1.1.7 (first identified in the UK), B.1.351 (first identified in South Africa), and P1 (first identified in Brazil) continue to spread from locations with (a) more than 5 sequenced variants, and (b) reports of community transmission, to adjacent locations following the speed of variant scale-up observed in the regions of the UK.
- In one-quarter of those vaccinated, mobility increases toward pre-COVID-19 levels.

The **worse scenario** modifies the reference scenario assumptions in three ways:

- First, it assumes that variants B.1.351 or P1 begin to spread within 3 weeks in adjacent locations that do not already have B.1.351 or P1 community transmission.
- Second, it assumes that all those vaccinated increase their mobility toward pre-COVID-19 levels.
- Third, it assumes that among those vaccinated, mask use starts to decline exponentially one month after completed vaccination.

The **universal masks scenario** makes all the same assumptions as the reference scenario but also assumes 95% of the population wear masks in public in every location.

Figure 19. Cumulative COVID-19 deaths until August 01, 2021 for three scenarios



Figure 20. Daily COVID-19 deaths until August 01, 2021 for three scenarios,



Figure 21. Daily COVID-19 infections until August 01, 2021 for three scenarios.



Figure 22. Comparison of reference model projections with other COVID modeling groups. For this comparison, we are including projections of daily COVID-19 deaths from other modeling groups when available: Delphi from the Massachussets Institute of Technology (Delphi; https://www.covidanalytics.io/home), Imperial College London (Imperial; https://www.covidsim.org), The Los Alamos National Laboratory (LANL; https://covid-19.bsvgateway.org/), and the SI-KJalpha model from the University of Southern California (SIKJalpha; https://github.com/scc-usc/ReCOVER-COVID-19). Daily deaths from other modeling groups are smoothed to remove inconsistencies with rounding. Regional values are aggregates from availble locations in that region.



Figure 23. The estimated inpatient hospital usage is shown over time. The percent of hospital beds occupied by COVID-19 patients is color coded based on observed quantiles of the maximum proportion of beds occupied by COVID-19 patients. Less than 5% is considered *low stress*, 5-9% is considered *moderate stress*, 10-19% is considered *high stress*, and greater than 20% is considered *extreme stress*.



Figure 24. The estimated intensive care unit (ICU) usage is shown over time. The percent of ICU beds occupied by COVID-19 patients is color coded based on observed quantiles of the maximum proportion of ICU beds occupied by COVID-19 patients. Less than 10% is considered *low stress*, 10-29% is considered *moderate stress*, 30-59% is considered *high stress*, and greater than 60% is considered *extreme stress*.



More information

Data sources:

Mask use data sources include Premise; Facebook Global Symptom Survey (This research is based on survey results from University of Maryland Social Data Science Center) and the Facebook United States Symptom Survey (in collaboration with Carnegie Mellon University); Kaiser Family Foundation; YouGov COVID-19 Behaviour Tracker survey.

Vaccine hesitancy data are from the COVID-19 Beliefs, Behaviors, and Norms Study, a survey conducted on Facebook by the Massachusetts Institute of Technology (https://covidsurvey.mit.edu/).

Vaccine hesitancy data are from the Facebook Global Symptom Survey (This research is based on survey results from University of Maryland Social Data Science Center), the Facebook United States Symptom Survey (in collaboration with Carnegie Mellon University), and from the Facebook COVID-19 Beliefs, Behaviors, and Norms Study conducted by the Massachusetts Institute of Technology.

Genetic sequence and metadata are primarily from the GISAID Initiative. Further details available on the COVID-19 model FAQ page.

A note of thanks:

We wish to warmly acknowledge the support of these and others who have made our COVID-19 estimation efforts possible.

More information:

For all COVID-19 resources at IHME, visit http://www.healthdata.org/covid.

Questions? Requests? Feedback? Please contact us at https://www.healthdata.org/covid/contact-us.